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Abstract
Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis. In order to improve outcomes, 
there is a critical need for improved tools for detection, accurate staging and resectability 
assessment. This could improve patient stratification for the most optimal primary treatment 
modality. Molecular imaging, used in combination with tumor-specific imaging agents, can 
improve established imaging methods for PDAC. These novel, tumor-specific imaging agents 
developed to target specific biomarkers have the potential to specifically differentiate between 
malignant and benign diseases, such as pancreatitis. When these agents are coupled to various 
types of labels, this type of molecular imaging can provide integrated diagnostic, non-invasive 
imaging of PDAC as well as image-guided pancreatic surgery. This review provides a detailed 
overview of the current clinical imaging applications, upcoming molecular imaging strategies for 
PDAC, and potential targets for imaging, with an emphasis on intraoperative imaging applications.
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INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) accounts for about 90% of all pancreatic 
neoplasms and is the fourth most common cause of cancer-related deaths in developed 
countries.1 PDAC has a dismal prognosis, with a five-year survival rate of less than 5%. 
Pain, jaundice and weight loss are the most common presenting symptoms but in the early 
stages of the disease, these symptoms may be subtle which often leads to delayed diagnoses.
2
 The median size of PDAC at the time of diagnosis is ~3.1 cm, and these statistics have not 
changed in the past three decades despite advances in imaging technologies, as well as in 
vitro diagnostic testing methods.3 Resection of tumors while they are small, well-defined 
and localized results in a higher chance of complete tumor clearance which translates into 
greater patient survival rates.3,4
Only 15% to 25% of patients are eligible for curative resection at their initial diagnosis, due 
to locoregional spread and metastasis.5,6 More precise detection methods can lead to 
improved patient stratification for the most optimal primary treatment modality; either 
surgery or systemic (neoadjuvant) therapy. This selection can prevent patients from 
undergoing resections without any oncologic benefit. Another advantage of precise 
visualization of the tumor could be a more radical resection. Tumor margin-positive (R1) 
resections occur in up to 70% of PDAC cases, leading to a high number of locoregional 
recurrence.7,8 This means that for all patients diagnosed with PDAC, only 15% of these 
patients will receive a radical, tumor-margin negative resection and have a chance for 
prolonged survival. Therefore, improved tools for diagnosis, accurate staging, and more 
effective, tumor-margin negative pancreatic surgeries are crucial for improving patient 
outcomes.9
Imaging techniques play an important role in the diagnosis of PDAC. Current clinical 
imaging protocols include transabdominal ultrasound, computed tomography (CT) and/or 
magnetic resonance imaging (MRI) for disease staging and prediction of resectability.1 
Endoscopic ultrasound (EUS) can complement these imaging methods with valuable staging 
information as well as the opportunity of tissue diagnosis by fine-needle aspiration.10
Molecular functional imaging has the potential to play an important role in PDAC 
management and be of complementary value to these conventional imaging techniques. It 
could be used for earlier tumor detection, and improved characterization, staging, and 
response assessment to neoadjuvant therapy. It could also serve as a guide for surgery during 
diagnostic laparoscopy and tumor resection. Possible imaging modalities for molecular 
imaging include molecularly-targeted contrast-enhanced transabdominal (CEUS) and EUS, 
CT, MRI, positron emission tomography (PET), photoacoustic imaging (PAI), fluorescence 
molecular imaging, and Raman optical imaging (Fig. 1).
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Recently, Laeseke et al. published a review focused on the role of molecular imaging in 
early detection of PDAC.11 The current review gives an overview of the status of clinical 
imaging applications, the advances of molecular imaging strategies, and most optimal 
imaging targets for PDAC, with a special emphasis on intraoperative applications.
CURRENT DIAGNOSTIC IMAGING TOOLS FOR PDAC
Transabdominal and endoscopic ultrasound
Ultrasound (US) is often the initial diagnostic assessment used in patients presenting with 
jaundice, weight loss, and abdominal pain. US is a relatively inexpensive, portable, 
noninvasive, and widely available tool. However, the sensitivity and accuracy of US is highly 
dependent on the operator’s skills, degree of disease progression and body habitus of the 
patient. Therefore, sensitivity of conventional US for detecting PDAC varies widely and 
ranges from 95% in tumors > 3 cm to 50% in tumors < 1 cm.12 In addition, it is difficult to 
differentiate between PDAC and inflammatory diseases such as pancreatitis using US 
technology.
EUS has become a valuable diagnostic tool for PDAC since it allows for tissue sampling and 
cytological evaluation, both of which can provide a definitive diagnosis.13,14 For the 
evaluation of solid pancreatic tumors, EUS detects lesions <2 cm with greater sensitivity 
(98%) than CT (86%). On the other hand, EUS also has important limitations in the 
evaluation of solid pancreatic lesions. First, there is substantial operator-dependence, 
resulting in variable sensitivity ranging from 57% to 81%.15,16 Second, the sensitivity is 
relatively poor (80%) when detecting PDAC in patients with pancreatitis.17 And finally, the 
invasive nature of EUS is a significant disadvantage of this technique.
Computed Tomography
Multiphase multi-detector row CT (MDCT) with intravenous contrast is the diagnostic test 
of choice for suspected pancreatic lesions. MDCT has the highest accuracy in determining 
the extent of primary tumor, locoregional extension, vascular invasion, distant metastases 
and resectability.14 MDCT is used to predict resectability of PDAC with a positive predictive 
value (PPV), sensitivity and specificity of 89%, 96% and 33–72%, respectively.18,19 An 
additional advantage of MDCT imaging is the possibility to detect extrapancreatic spread by 
perineural invasion.20 This is of great importance since these patients have significantly 
reduced survival after pancreaticoduodenectomy.21 CT perfusion can be used to differentiate 
between low and high grade PDAC, by using peak enhancement intensity values and blood 
volume parameters.22 Despite its sensitivity, MDCT cannot reliably detect small lesions 
(<1cm), differentiate between malignant lesions and benign conditions, or detect 
isoattenuating primary tumors.23
Magnetic Resonance Imaging
MRI has a reported sensitivity and specificity for diagnosis of PDAC of 85–93% and 72–
79%, respectively.24,25 MRI has advantages over CT regarding improved soft tissue contrast 
resolution and the absence of ionizing radiation. This leads to several situations were MRI is 
preferred above CT; such as with small tumors, isoattenuating lesions, and fatty infiltration 
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in the pancreatic head.26 In addition, there are alternative sequences when using MRI, such 
as magnetic resonance cholangiopancreaticography (MRCP) which can be used to image the 
biliary and pancreatic ducts in detail. MRCP has comparable sensitivity to the more invasive 
endoscopic retrograde cholangiopancreaticography (ERCP) in diagnosing PDAC.27 Another 
potential sequence is diffusion-weighted images (DWI), with this technique the difference in 
diffusion of water molecules is visualized by using the apparent diffusion coefficient (ADC). 
PDAC tends to have low ADC values due to high levels of fibrosis. This methods is helpful 
for the identification of subtle lesions with diffusion restriction.26 Due to its high soft tissue 
contrast MRI is the preferred modality for assessing cystic lesions in the pancreas.28 
Another important advantage of MRI over CT is the more precise detection of enlarged 
lymph nodes and distant metastases.28 A disadvantage of both CT and MRI, is that neither 
can reliably distinguish residual or necrotic tumor from fibrosis and radiation changes after 
treatment.
PET Imaging
Currently, PET is the only molecular imaging technique used for PDAC. It enables whole 
body imaging to allow staging of diseases, similar to CT and MRI. [18F]-2-fluoro-2-deoxy-
glucose (18F-FDG)-PET has an established role in the work-up of various malignancies. The 
normal pancreas has low glucose usage compared to PDAC, so areas with increased uptake 
can be visualized and point towards potential lesions. Because the metabolic activity of a 
tumor is expressed by the degree of 18F-FDG uptake it is possible to predict tumor 
aggressiveness and even survival in patients by the degree of uptake.29,30 The average 
sensitivity and specificity of 18F-FDG for PDAC are 94% and 90% respectively, compared 
to 82% and 75% for CT.31 Choi et al. reported the use of 18F-FDG-PET to detect 
biologically active tumor volumes and therefore to assess treatment effectiveness.32 A recent 
multi-center trial in the UK with 550 patients looking at the diagnosis of PDAC showed a 
sensitivity of 92.7% for FDG PET/CT compared to 88.5% for MDCT (P = 0.010) and a 
specificity of 75.8% compared to 70.6% (P = 0.023).33 A problem of using 18F-FDG uptake, 
is that glucose metabolism is not specific for malignant processes, and physiologic uptake 
can be found in normal tissues as well as in inflammatory tissue which might lead to false-
positive findings, causing a similar appearance for pancreatitis and PDAC.34
CURRENT INTRA-OPERATIVE IMAGING TOOLS
A major limitation of the aforementioned imaging techniques, such as CT, MRI or PET is 
the fact that these techniques cannot be applied as intraoperative imaging tools due to altered 
positioning of the body, and tissue manipulation by the surgeon.35 For brain cancer surgery, 
the use of MRI-guided resection has almost become standard practice.36 Unfortunately, this 
method is time-consuming, costly. Therefore, chances are low that MRI-guided resection 
will be widely-implemented outside the field of brain cancer surgery. Currently, the only 
tools available for a pancreatic surgeon to ensure complete tumor resection are visual and 
tactile information, frozen-section analysis by a pathologist, and intra-operative ultrasound.
Intra-operative frozen-section analysis (IFSA) is commonly performed to determine 
resectability when unanticipated locoregional spread is identified during surgery and to 
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ensure negative final margins after resection.37 Although frozen section analysis is 
commonly used to determine successful ablation, it is time-consuming,and only samples a 
small fraction of the wound bed which could lead to false-negative results. During surgery, if 
the IFSA of the resection margin turns out to be positive, additional pancreatic tissue is often 
removed in an effort to clear the margin. Only a few single institutional studies have 
assessed the value of this surgical maneuver so far and it is shown that there is actually no 
improved overall survival when additional IFSA-guided resection is performed.38–40 IFSA 
has a reported low incidence of false-positive results, but the amount of false-negative results 
has ranged widely from 1.2% to 75%.41,42 This relatively high incidence of false-negative 
results could indicate that preoperative imaging and possibly even surgical judgement are 
more reliable than a negative IFSA.
Intra-operative Ultrasound
Currently, the only intra-operative imaging technique to help the surgeon delineate PDAC 
from its surrounding structures is anatomical intraoperative ultrasound. The ability to 
provide high resolution real-time imaging, along with accurate lesion detection, has 
established the role of intraoperative ultrasound (IOUS) in PDAC surgery. IOUS can be used 
for intraoperative guidance and localization of lesions, for determining resectability, surgical 
planning, differentiation between cystic and non-cystic lesions, and metastatic survey.43,44 
IOUS also has disadvantages since it is less reliable for detecting superficial and small 
lesions compared to visual and tactile methods.45 Another disadvantage is its operator 
dependence; substantial training and experience are essential for generating and interpreting 
useful images for intra-operative surgical decision-making.12,46
THE NEED FOR ADVANCED MOLECULAR IMAGING IN PDAC
To be able to improve detection and patient stratification for treatment, there is a critical 
need to develop and improve imaging methods that specifically recognize cancer.47 In 
current practice, the accurate identification of tumors is mainly subjective and relies heavily 
on the surgeon’s experience leading to a significant variability in surgical outcomes.48 This 
inability to exactly identify tumors intraoperatively could result in: 1) Incomplete resection 
of tumors that could otherwise have been resected completely; 2) Attempt to resect tumors 
which should have been identified as locally advanced tumors; 3) Incomplete lymph node 
clearance due to lack of knowledge of the involved or potentially involved lymph nodes, and 
4) Resection of the primary tumor in the presence of visually occult micrometastasis. In each 
of these situations, patients undergo operations with little or no oncological benefit, but with 
a high risk of deterioration of quality of life due to surgery in their end stage of life. There 
are two other challenges a surgeon faces when resecting PDAC. First, both the benign 
pancreatitis and malignant PDAC have abundant stroma, and therefore both entities are 
difficult to distinguish using conventional imaging techniques. Second, the introduction of 
neoadjuvant treatment regimens such as FOLFIRINOX, leading to a 51% increase in tumors 
becoming resectable after 4 months of neoadjuvant treatment.49 One of the major drawbacks 
after neoadjuvant treatment is that conventional imaging modalities, such as CT and MRI, 
are often not able to differentiate between viable tumor and chemoradiation-induced tumor 
necrosis and fibrosis, and, therefore, prediction of resectability is limited.50 Neoadjuvant 
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treatment effects make differentiation between (vital) tumor and fibrotic pancreatic tissue 
even harder for surgeons during the operation.
Tumor-targeted molecular imaging could provide crucial information in these situations. 
Molecular imaging can either be performed by using conventional imaging techniques in 
combination with tumor-specific imaging agents, or by the development of novel imaging 
techniques, such as fluorescent, photoacoustic and Raman optical imaging. Currently, 
several first-in-human clinical trials are conducted using these techniques in pancreatic 
cancer patients.
TUMOR-TARGETED MOLECULAR IMAGING STRATEGIES FOR PDAC
A molecular imaging approach using imaging agents that target molecular features of cancer 
could lead to more precise diagnoses.13 The common consensus is that PDAC evolves from 
precursor lesions that transform into invasive carcinoma through a multistep process, that 
involves the progression from pancreatic intraepithelial neoplasia (PanIN) into PDAC.51 
Genetic alterations, such as mutations in the KRAS oncogene or p53, DPC4, and BRCA2 
tumor suppressor genes affect a core group of signaling pathways. The processes that are 
altered in PDAC lead to the expression of specific biomarkers, and these changed 
biomarkers may serve as targets for tumor-specific imaging.52 Potential biomarkers for 
tumor-specific targeting must possess certain characteristics such as diffuse upregulation 
through tumor tissue, strong upregulation compared to the expression in normal and 
surrounding tissue, and localization on the cellular membrane.53, 54 An effective molecular 
imaging agent needs to demonstrate a high ratio of specific to non-specific binding to make 
sure the signal truly reflects the molecular imaging target.
There are numerous categories of available molecular imaging agents including small 
molecules, peptides, aptamers, antibodies, engineered protein fragments, nanoparticles, or 
micro-sized contrast agent. Each of these types of agents is different in size and thus 
possesses different pharmacokinetic characteristics (Table 1). It goes beyond the scope of 
this review to describe all the different molecular imaging agents in detail; however, please 
refer to the following review for further details.55
The most important groups of targeted imaging agents that are currently being explored are 
based on targeting specific receptors that are upregulated during the progress of PDAC 
development. For example, global expression analysis of PDAC has revealed that claudin 4 
and prostate stem cell antigen (PSCA) are upregulated in the vast majority of PDACs.56,57 
Given the membrane localization and the presence of an extracellular domain, these proteins 
are attractive candidates for targeted imaging. Additionally, claudin 4 has a high expression 
in high grade PanIN lesions, indicating the potential to detect lesions before development 
into an invasive carcinoma.58 Other targets employed for tumor-specific imaging of different 
cancer types are not applicable for PDAC due to co-expression of these receptors on normal 
pancreatic tissue (somatostatin, secretin, bombesin, cholecystokinin, vasoactive intestinal 
peptide).59–62 Another possibility for PDAC would be the use of a combined target, against 
both tumor and surrounding stroma, which can be of significant advantage because of the 
abundance of stroma in PDAC, such as the target uPAR.63 Since several potential imaging 
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targets have been identified for normal pancreatic tissue, an alternative strategy could be to 
visualize normal tissue while abnormal/cancerous would be visualized by a lack of imaging 
signal. For example by targeting the bombesin receptor, PDAC would appear by a lack of 
contrast agent uptake.64 However, specificity of those potential molecular imaging targets 
compared to pancreatitis is still to be determined.
MOLECULARLY TARGETED IMAGING AGENTS FOR CURRENT CLINICAL 
IMAGING MODALITIES
Molecularly Targeted (Intra-operative) Ultrasound
Contrast-enhanced US (CEUS) involves the use of targeted microbubble imaging agents and 
specialized imaging techniques. For the diagnosis and differentiation of pancreatic 
malignancies, transabdominal CEUS has generated test characteristics comparable to, or 
better than other diagnostic modalities such as conventional ultrasound and CT.65 CEUS 
with a non-specific agent showed similar sensitivity to contrast-enhanced CT for the 
detection of PDAC (91.7% and 97.2%, respectively) and of pancreatitis (82.1% and 67.9%, 
respectively).66 Intra-operative CEUS is well established in liver surgery, but it has not yet 
found its place in PDAC. However, CEUS provides a potential for the detection of small 
tumors, since it shows improved sensitivity and specificity compared to multi-detector CT 
(MDCT) for pancreatic lesions <2 cm; 91% vs 71% and 94% vs 92%, respectively.67
Ultrasound using molecularly targeted microbubbles would be a tool to increase sensitivity 
and specificity even further.68 Targeted imaging agents differ from those initially developed 
by the presence of a targeting moiety able to link the microbubble to the selected biomarker.
68–72
 A disadvantage of microbubbles is their relatively large diameter. Therefore, they 
remain within the vascular compartment after intravascular administration, which limits 
targeting to molecules that are overexpressed on the surface of endothelial cells of the tumor 
vasculature (Fig. 2).73
Molecular-targeted Agents for Ultrasound Imaging—The formation of new blood 
vessels is a fundamental process during tumor progression. Under hypoxic conditions, which 
are required for effective tumor angiogenesis, expression of hypoxia-inducible factors is 
induced in endothelial vessels resulting in vascular endothelial growth factor receptor 
(VEGFR) expression.74 VEGFR is a receptor tyrosine kinase that mediates most of the 
proangiogenic activity of VEGF. Our group has previously shown that VEGFR2 is a 
promising target for detection of PDAC. In a cohort of 129 patients, VEGFR2 was 
abundantly expressed in up to 72% of all PDAC cases.75 Microbubbles developed to 
recognize VEGFR2, integrin and endoglin were used to visualize tumor angiogenesis by 
ultrasound imaging in PDAC of genetically engineered mouse models.76,77 Recently, first-
in-human clinical trials using a VEGFR2-targeted agent have been performed.72 and shown 
great potential in detecting breast and ovarian cancer.78 Foygel et al discovered and validated 
thymocyte antigen 1 (Thy1) as a new PDAC imaging target.79 Thy1 is a marker expressed 
on the neovasculature of PDAC and shown to be differentially expressed in PDAC versus 
pancreatitis and normal pancreatic tissue in humans.79 In vivo imaging studies with a 
genetically engineered mouse model of PDAC showed a 4–5.5-fold increased signal in 
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PDAC compared to normal parenchyma when using a novel Thy1-targeted microbubble.79 
Clinical trials with these agents in PDAC patients have not yet been performed, but are 
planned for the future.
Molecularly Targeted MRI
MRI has a fairly high sensitivity as described above, but increased sensitivity could be 
realized by increased enhancement of the tumors using molecularly-targeted contrast agents. 
Pirollo et al described a way to systemically deliver the imaging agent gadolinium in a 
tumor-targeted nanocomplex leading to better tissue penetration, and therefore better 
visualization of PDAC in an orthotopic animal model.80
Molecular-targeted Agents for MRI—Studies using targeted MR imaging against 
biomarkers, such as plectin-1 and EGFR, showed tumor targeting both ex vivo and in vivo.
81,82
 ScFvEGFR-IO injection lead to 4.8 fold specific decrease in MRI signal in the tumor 
area, compared to a non-targeted particle.81 Mucin-1 is a tumor-specific antigen that is one 
of the early hallmarks of carcinogenesis in a broad range of tumors, including PDAC.83 
Medarova et al. developed a dual-modality imaging agent targeting Mucin-1 in an orthotopic 
PDAC model for both MRI and NIRF imaging.83,84 A potential drawback for clinical use of 
mucin-1 as imaging target is that this antigen expression is down-regulated after neoadjuvant 
gemcitabine therapy.85
Molecularly Targeted PET
The specificity of PET imaging could be improved by using a more disease-specific imaging 
agent compared to FDG-PET (Fig. 3). There are several preclinical examples of disease-
specific PET imaging in PDAC, and recently, for the first time a first-in-human trial is 
performed by Kimura et al. using a tumor-specific peptide targeting integrin αvβ6, [18F]FP-
R01-MG-F2, for the detection of PDAC. This study shows proof even in this cancer type 
with dense stroma, an imaging agent can penetrate the tumor [Kimura et al under review].
Molecularly Targeted Agents for PET Imaging—In preclinical setting, several targets 
are explored. Aung et al described the use of 64Cu-RAFT-RGD, targeting αvβ3, for imaging 
an orthotopic pancreatic tumor-bearing mouse model showing higher detectability of cancer 
cells as compared to 18F-FDG-PET.86 Carbohydrate antigen 19-9 (CA 19-9) is widely used 
as a serum marker of PDAC, and it is known to be presented on the tumor cells of 
approximately 90% of all PDAC patients.87, 88 A dual-modal probe targeting CA 19-9 using 
PET and near-infrared fluorescence imaging was developed by Houghton et al. This probe 
identified metastases and map sentinel lymph nodes in an orthotopic PDAC mouse model 
via both PET-computed tomography (PET/CT) and NIRF imaging.89 Unfortunately, CA 
19-9 is also presented on pancreatitis and therefore, this agent will be of limited value in the 
clinic.90 The earlier mentioned cell surface receptor integrin αvβ6 is a well-known target for 
molecular imaging of PDAC since over 90% of human PDAC cases overexpress αvβ6.91–96 
Hackel et al. used two version of an 18F-labeled integrin αvβ6–targeted cystine knot peptide 
for successful PET-imaging of PDAC xenografted tumors in mice.91 Tissue factor (TF), a 
transmembrane glycoprotein, is also known to be upregulated during tumor growth and 
metastasis. There is a strong correlation between the aberrant expression of TF, staging and 
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overall survival in PDAC, making TF an attractive imaging target.97, 98 Hong et al. 
developed a PET tracer, 64Cu-NOTA-ALT-836, for imaging TF expression using the 
chimeric antihuman TF monoclonal antibody, ALT-836. Serial PET revealed that the uptake 
of (64)Cu-NOTA-ALT-836 was significantly higher in TF positive tumors compared to 
negative tumors.99 Activated leukocyte cell adhesion molecule (ALCAM) homotypic 
interactions promote primary tumor growth, and this cell-surface glycoprotein is upregulated 
on cancer cells relative to normal cells.100 McCabe et al. imaged ALCAM expression by 
using a cysteine-modified diabody, CysDb, which binds specifically to ALCAM-positive 
cells with a binding affinity of 1–3 nM and microPET images showed specific targeting of 
positive tumors.101 Clinical translation of this probe seems unlikely due to its relatively short 
half-life and potential nephrotoxicity due to high renal exposure of the beta-emitting 
radionuclide. Alternatively, this agent could be labeled with 18F, which would overcome 
these limitations. Lastly, the transferrin receptor (TfR) was investigated as a possible target 
for PET imaging in PDAC. TfR is a cell-surface receptor involved in iron uptake. It is 
overexpressed on cells with high proliferation rates, and about 80% of all PDAC patients 
show high TfR expression.102 Sugyo et al. developed a PET probe targeting TfR, with a 
mean tumor-to-muscle ratio of 9.8 at day 6 in a subcutaneous PDAC model. However, a 
major disadvantage of this probe is its high accumulation in the liver, which could hinder 
detection of tumor tissue in close proximity to the liver.103
INTRAOPERATIVE MOLECULAR IMAGING TECHNIQUES: POTENTIAL FOR 
IMPROVED INTRA-OPERATIVE PERFORMANCE
Fluorescence Molecular Imaging
Over the last few years, intraoperative imaging technologies using near-infrared (NIR) 
fluorescence have made enormous progress. The volume of publications in this field has 
increased eightfold in the literature in the last 10 years.104 Benefits of Fluorescence imaging 
using NIR fluorescent light include the ability to image in real time using an NIR 
fluorescence camera system without impeding the current clinical workflow. If surgeons 
were able to resect tumors and preserve normal structures more easily, time of surgery could 
be shortened, thereby reducing anesthesia time and its associated risks. Furthermore, this 
could subsequently lower rates of recurrence and complications, which would improve 
patient outcomes and even drive down costs.35 Fluorescence imaging using NIR fluorescent 
light has already been established as a powerful tool for guiding precise intra-operative 
positioning in other types of cancer such as liver metastases,105 breast cancer,106,107 ovarian 
cancer,108 melanoma,109 vulvar cancer,110,111 and cervical cancer.112,113 Currently, only the 
non-specific dyes methylene blue (MB) and indocyanine green (ICG) are approved for 
clinical use by the FDA and in order to determine the true clinical benefit of tumor-specific 
fluorescent imaging, developing and clinically assessing tumor-specific imaging agents will 
be essential (Fig. 4). Recently, two first-in-human clinical studies are performed by our 
research groups using tumor-specific intra-operative imaging in PDAC, targeting CEA with 
SGM-101 [Hoogstins et al under review] and EGFR with cetuximab-IRDye800 [Tummers 
WS et al. accepted]. Hoogstins et al performed a phase 1 clinical trial targeting CEA, with a 
700nm fluorescent agent [Hoogstins et al under review]. Tummers et al conducted a clinical 
trial using both NIR and PA imaging for the tumor-specific detection of PDAC with 
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cetuximab-IRDye800 [Tummers et al accepted]. In both trials successful PDAC imaging 
could be performed, however interfering autofluorescence was seen with the fluorescent 
agent at 700 nm. These trials show the first proof that this imaging technique is possible in 
PDAC, despite the idea that the dense stroma of PDAC will restrict targeted-imaging and 
therapy. Tummers et al. even show proof of drug penetration into the a single tumor duct.
Molecular-targeted Agents for Fluorescent Molecular Imaging—As described 
above, until now only agents targeting the CEA and EGFR receptor are used in clinical trials 
for NIR fluorescent imaging of PDAC. With cetuximab-IRDye800, it was even possible to 
establish a significantly different fluorescent signal in PDAC compared to peritumoral 
inflammation [Tummers et al accepted]. Furthermore, only preclinical work is performed for 
the identification of intraoperative imaging agents and targets. As mentioned before, αvβ6 
seems to be a reliable target for PDAC. Gao et al. synthesized an integrin αvβ6-targeted 
near-infrared phthalocyanine dye-labeled agent, termed Dye-SA-B-HK, and investigated it 
for possible targeted theranostics. Dye-SA-B-HK specifically bound to integrin αvβ6 in 
vitro and in vivo with high receptor binding affinity, and when used for surgical guidance, 
the tumors were successfully removed completely.93 The main advantage of this agent 
compared to nanoparticles is the size of this agent, which gives the ability to extravasate, and 
faster excretion. Zhang et al. recently developed an optical imaging agent, suitable for both 
fluorescent and photoacoustic imaging. This imaging agents consists of a cysteine knottin 
targeting αvβ6 conjugated to the dye Atto-740, A740-R01. The agent was able to 
successfully detect integrin αvβ6 both in vitro and in vivo by photoacoustic and 
fluorescence imaging.114
Cathepsin E (Cath E) is a tumor-associated intracellular non-lysosomal aspartic proteolytic 
enzyme. In normal physiology Cath E is expressed in immune cells. In the pancreas, Cath E 
is present in PanIN lesions and PDAC, but not in normal pancreatic tissue.115 Targeting Cath 
E can be done by Cath E-activatable imaging probes. These agents are nonfluorescent or 
produce low-fluorescence in their unactivated state, but become fluorescent after activation 
as a result of binding to their molecular target such as a tumor-specific enzyme.35,115,116 
Using an activatable imaging probe has several advantages. First, in its native state the 
quenched probe is optically silent, thereby minimizing background fluorescence and 
enhancing tumor-to-background ratios. Second, protease recognition sites allow for specific 
activation of probes. Finally, probes can be designed to be activated by different proteases, 
thus permitting specific detection of tumors with different protease expression profiles.
117,118
 Recently, Whitley et al. published results of the first-in-human trial using a protease-
activated fluorescent imaging probe, LUM015, to detect soft tissue sarcoma or breast cancer. 
This study demonstrated the probe’s safety in humans and also its tumor-specific 
fluorescence.119
Despite improved tissue penetration as compared to visible light, an essential limitation of 
the use of NIR fluorescence imaging intraoperatively is its inability to visualize structures 
deeper than approximately 5 – 8 mm below the surface.35,120 As a result of this limitation, 
the field has been shifting towards developing a combination of different forms of imaging 
modalities, such as PAI, as described in the clinical trial of Tummers et al.
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Photoacoustic Imaging
Photoacoustic imaging (PAI), also referred to as optoacoustic imaging, is a relatively new 
imaging technique with significant promise. PAI provides real-time, noninvasive imaging of 
the optical absorption properties of tissues. PAI relies on the photoacoustic effect; a pulsed 
nanosecond-long red-shifted laser beam that is used to stimulate localized thermoplastic 
expansion of the tissues. This expansion generates pressure waves, synonymous with those 
produced in ultrasound, which can be detected by a transducer and converted into images.120 
The combined use of light and sound gives PAI an important advantage over other imaging 
modalities including CT, PET or ultrasound because it provides unique scalability of its 
spatial resolution. The penetration up to clinically relevant depths, namely from 6 mm to 5 
cm, is an important factor for its potential intraoperative use during PDAC surgery (Fig. 5).
120–123
PAI can be performed based on two methods: by relying on the differences in the optical 
absorption properties of endogenous tissue or by using exogenous imaging agents targeting a 
specific molecular process of interest. Exogenous imaging agents have the ability to greatly 
enhance the contrast generated by PAI. The selection of an imaging agent will depend on the 
application for which it will be used. Design considerations and requirements for a PAI 
imaging agent include: (1) ease of synthesis, (2) overall size on the nano-scale or smaller in 
order to extravasate the vascular compartment, (3) a large absorption cross-section of light in 
the NIR wavelength region where light penetration into tissue is maximized, (4) a surface 
chemistry that allows simple bioconjugation of targeting moieties, (5) proven safety profile, 
and (6) a structural and molecular biostability in biological fluids.124 Photostability is also 
very important for these agents as they often suffer from loss of optical absorption 
(photobleaching) due to exposure to prolonged pulsed laser irradiation.125 Nanoparticles are 
the most commonly used types PAI agents, and especially gold nanoparticles, single-walled 
carbon nanotubes (SWNT), and quantum dots.120,124,126,127 Gold nanoparticles have an 
advantage in that their optical properties are highly tunable over the NIR spectrum by 
varying their size and shape. However, they have major disadvantages since they consist of 
gold, which is not approved for human use, and they can become deformed after extended 
exposure to laser radiation.128 SWNTs absorb light over a broad spectrum, and targeting 
agents can easily be conjugated for molecular imaging. Quantum dots are strongly 
fluorescent and have been shown in multiple studies to be successful PAI agents in PDAC.
129,130
 Other important disadvantages of gold nanoparticles, SWNTs, and quantum dots are 
their inability to sufficiently extravasate and the potential long term effects due to retention 
in the reticuloendothelial system which are not an issue for small particles.131,132
As previously stated, the strengths of PAI include its clinically relevant depth penetration 
compared to fluorescence imaging and the potential to visualize extravascular molecular 
imaging targeted compared to molecular CEUS. The main disadvantages of PAI are its 
inability to image through bone or air-filled structures, and the fact that no commercial intra-
operative systems are available for now.55 Clinical applications for molecular photoacoustic 
imaging are still being explored. For diagnostics in PDAC, PAI could potentially be used 
during EUS in order to improve the sensitivity of the procedure. Studies investigating the 
intraoperative use of PAI are limited, and only described by Tummers et al. By targeting the 
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EGFR receptor, a significant difference was shown in PA signal in the tumor and 
surrounding pancreatic tissue. This indicates that intraoperatively PAI could potentially help 
determining the extent of the tumor infiltration before removal, tumor delineation, and the 
completeness of removal following resection and also play an important role in the 
assessment of metastases and lymph node status.120
Molecular-targeted Agents for Photoacoustic Molecular Imaging—In preclinical 
studies, the first use of targeted photoacoustic imaging using SWNT was described by De La 
Zerda et al. in 2008. Intravenous administration of SWNT conjugated to cyclic Arg-Gly-Asp 
(RGD) peptides in mice bearing tumors showed eight times greater photoacoustic signal 
compared to mice injected with non-targeted nanotubes.127 Levi et al. developed and 
validated both tumor-specific PAI agents for prostate cancer, against gastrin-releasing 
peptide receptor,133 and for follicular thyroid carcinoma, against MMP-9.134 Both agents 
showed increased PAI signal compared to a control agent. Conjugated polymers (CPs) are 
upcoming optical imaging agents that have unique chemical and optical properties thus 
allowing them to be used as imaging agents for PAI among other technologies.135 
Balasundaram et al. used folate-CP dots for the molecular imaging of breast cancer and 
showed a strong PA signal compared to non-specific CP dots.136 Promising PAI agents are 
activatable agents, as firstly described by Levi et al. targeting a proteolytic enzyme, e.g. 
MMP-2, which is photoacoustically silent before cleavage and leads to PAI signal after 
activation by the target.137
To tackle the abovementioned limitation fluorescence guided surgery is facing with limited 
depth penetration, PAI could help determining the extent of tumor before removal, and the 
completeness of the resection intraoperatively. On the other hand, fluorescent imaging has a 
superior sensitivity for superficial lesions. By combining the two modalities, the strengths of 
both NIR fluorescence imaging and PAI have the potential to overcome the limitations of the 
individual techniques in a combinatorial fashion.
Raman Optical Imaging
Raman optical imaging is based on the Raman effect, a process discovered by 
Chandrasekhara Venkata Raman in 1928 that is based on the inelastic scattering of light. 
Objects made of different molecular compositions will scatter light differently and produce 
unique spectra that are a function of the chemical bonds contained in the molecule of 
interest. Unfortunately, Raman scatter is very weak, with less than one in a million incident 
photons experiencing this effect.120,138,139 When the scattering molecule is placed on a 
surface of a roughened plasmonic substrate, the signal is increased by many log orders and is 
known as surface-enhanced Raman scattering (SERS).140,141 A major advantage of Raman 
optical imaging is the potential to detect multiple SERS nanoparticles simultaneously (a 
process called multiplexing), by modifying the Raman active layer that is absorbed onto the 
metal surface.138 Raman spectroscopy is recently tested ex vivo on human colon tissue. 
Zavaleta et al developed a Raman spectroscope in combination with a multiplexed panel of 
tumor-targeting Raman nanoparticles, to rapidly distinguish between normal and 
precancerous tissues and to identify flat lesions in the colon.142 This technology could be 
used for helping endoscopists or surgeons to delineate tumors while performing procedures.
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143,144
 Additionally, Jermyn et al. developed a handheld contact Raman spectroscopy probe 
for the detection of cancer cells in the human brain. Intra-operatively, they were able to 
differentiate normal brain from cancer and normal brain invaded by cancer with a cellular 
resolution with sensitivity of 93% and specificity of 91% in humans.145 Kircher et al 
described a MRI-PAI-Raman imaging nanoparticle to delineate the margins of brain tumors. 
This triple-modality-nanoparticle approach combines the strengths of the three modalities 
and leads to more accurate brain tumor imaging and resection in mouse models.146 A 
variation on Raman spectroscopy, transmission Raman spectroscopy, has enabled 
identification of calcifications at depths of up to 2.7 cm in breast tissue.147 This technique 
could potentially be used in the differentiation between PDAC and pancreatitis, since the 
latter is known for containing abundant calcifications. However, continued development of 
Raman spectroscopic instrumentation is needed in order to perform at the level necessary for 
intraoperative clinical use, including the design of a probe and the complete hardware which 
will need to be compact and easily integrated into the clinical OR.148
SUMMARY AND CHALLENGES FOR THE FUTURE
Despite great efforts to improve treatment for patients with PDAC in recent years, the 
disease still has the worst prognosis of all major solid cancers. Molecular imaging using 
tumor-targeting agents and various modalities has shown great potential, both clinically and 
preclinically, in order to bridge the gap between diagnostic and intraoperative imaging for 
PDAC treatment, and for monitoring response to perioperative chemo- and or radiotherapy. 
Multimodal imaging modalities also have significant potential when used as an integrated 
diagnostic and intraoperative technology, since this can overcome limitations of the 
individual modalities. At this point, feasibility of tumor-specific PET and fluorescence is 
shown in PDAC patients, and as soon as the other modalities are translated into the clinic the 
full potential of tumor-specific molecular can be assessed (Fig. 6).
The discovery of the perfect target (Table 2) and translation of molecular-targeted imaging to 
the clinic remains challenging due to the need for specific exogenous imaging agents in 
order to image the biochemical process of interest. The discovery and validation of such 
imaging targets is time-consuming and expensive, and rarely results in a clinically useful 
agent. Many of the imaging probes reported in animal models have failed to reach the clinic 
and are still in the investigational stage. Unfortunately, the extensive approval process of the 
FDA makes it impossible to quickly test imaging probes in a clinical pilot study in order to 
determine effectiveness in humans and thus save resources and concentrate on more 
promising probes.149 In addition, the added value of molecularly-targeted imaging to patient 
benefit still needs to be proven before wide-spread use of this technique is expected. This 
needs to be accomplished by increasing the number of human trials using a standardized 
technique to demonstrate safety and effectiveness. Although this is still far from current 
reality, the bulk of preclinical studies and the first successful clinical studies outlined in this 
review, show that more wide-spread clinical use is on the horizon.
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FIGURE 1. 
Schematic illustration of the key imaging modalities used for the diagnostics and potential 
intraoperative modalities for pancreatic cancer. Ultrasound, (endoscopic) ultrasound; CT, 
computed tomography; MRI, magnetic resonance imaging; PET, positron emission 
tomography. Representative images are shown of pancreatic cancer with the displayed 
modalities, expect for photoacoustic and raman optical imaging.
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FIGURE 2. 
A, Schematic overview of the principle of ultrasound molecular imaging. A molecularly-
targeted contrast agent (microbubble) is administered intravenously into the subject (in this 
case a mouse). Sound waves are transmitted into the subject by the transducer, the sound 
wave reflections are recorded and converted into images. Because of the size of 
microbubbles of several micrometers, the contrast agent remains intravascular and attaches 
to the target of choice (for example VEGFR2). Examples of in vivo molecular ultrasound 
images with microbubbles in (B) transgenic mouse model of PDAC, showing a strong signal 
when targeting VEGFR2 in focus of PDAC compared to normal pancreatic tissue, even in 
small PDAC lesions [From Pysz et al, 201576], and (C) in human with breast cancer using 
microbubbles targeting kinase insert domain receptor (MBKDR). Left panel: the anatomical 
image for reference, right panel: MBKDR accumulation in breast cancer lesion [Willmann et 
al, 201778]
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FIGURE 3. 
A, Schematic overview of the principle of tumor-targeted PET imaging, a suitable tracer will 
be administered into the subject (in this case a mouse). Depending on the size of the tracer, 
the tracer can target the cancer at multiple locations; e.g. intravascular, receptors on the cell 
membrane, or intracellular. B, Small-animal PET imaging. BxPC-3 (integrin αvβ6 pos) and 
293 (integrin αvβ6 negative) cells were xenografted in nude mice. PET images were 
acquired in tumor-bearing mice using a αvβ6-targeted cysteine knot (18F-fluorobenzoate-
R01) [From Hackel et al, 201391].
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FIGURE 4. 
A, Schematic overview of the principle of fluorescent imaging, a suitable targeted imaging 
agent with a fluorescent dye will be administered into the subject (in this case a mouse). The 
agent is visualized using a fluorescence imaging system, with an adequate excitation laser 
and camera able to detect the emitted light. The targeted agents migrate to the cellular 
targets to visualize the tumor in a target-specific manner, the imaging agent can target the 
cancer at multiple locations depending on the size; e.g. intravascular, receptors on the cell 
membrane, or intracellular. B, Top: schematic overview showing the principle of fluorescent 
imaging. Bottom: Intraoperative image showing the use of tumor-targeted fluorescent guided 
imaging during pancreatic cancer surgery.
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FIGURE 5. 
A, Schematic overview of photoacoustic imaging principle; after injection of a tumor-
targeting agent the imaging agent will target tumor cells and produces an enhanced 
photoacoustic signal, after excitation with a laser. The agent can target the cancer at multiple 
locations depending on the size; e.g. intravascular, receptors on the cell membrane, or 
intracellular. B, Top: Schematic overview showing the principle of photoacoustic imaging; 
the thermo-elastic expansion caused by heating of the tissue due to the laser will lead to 
acoustic waves that can be converted into both ultrasound and molecular images. Bottom: 
Tumor-targeted photoacoustic imaging. Mice bearing FTC133 tumors were 
photoacoustically imaged using 680 and 750 nm light before and after the injection of a 
MMP-targeting probe [From Levi et al, 2013134].
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FIGURE 6. 
A schematic overview of the principle of tumor-targeted imaging in pancreatic cancer, 
showing the most promising imaging modalities for early diagnosis and improved surgical 
treatment, and most promising targets for this purpose. Avβ6; Integrin αvβ6, CEA; 
Carcinoembryonic Antigen, EGFR; Epidermal growth factor receptor, Thy1; Thy-1 cell 
surface antigen, uPAR; Urokinase receptor, VEGFR2; Vascular endothelial growth factor 
receptor 2, Plec1; Plectin 1, Cath E; Cathepsin E.
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